The proposed class of Vmn2r9 Inhibitors encompasses a broad array of compounds that, through their action on various signaling molecules and pathways, possess the potential to indirectly modulate the activity or expression of Vmn2r9. This receptor, presumed to be part of the vomeronasal type 2 receptor family, plays a crucial role in the detection of pheromonal signals, with its activity mediated through complex intracellular pathways characteristic of G protein-coupled receptors. In the absence of direct inhibitors, the strategy employed focuses on altering the broader signaling landscape within which Vmn2r9 operates. By targeting key regulatory molecules and pathways-such as those involved in the production of cAMP, regulation of intracellular calcium levels, and activation of various kinases-these inhibitors can alter the cellular context and modulate the receptor's function. This approach not only provides a means to explore the biological functions of Vmn2r9 but also highlights the intricate web of cellular signaling pathways that govern sensory perception and response mechanisms at the molecular level.
Through this exploration, the selected compounds serve as valuable tools for investigating the physiological roles of Vmn2r9 and the mechanisms by which it contributes to pheromone detection and signaling. This strategy underscores the complexity of signaling networks and the nuanced approaches required to influence receptor activity indirectly. The strategic selection of these compounds offers a foundational basis for probing the signaling pathways and processes underpinning Vmn2r9's function, facilitating a deeper understanding of the molecular underpinnings of sensory signaling. This methodology exemplifies the broader principles of signal transduction and cellular communication, emphasizing the potential of targeted chemical intervention to unravel the signaling dynamics of specialized receptors such as Vmn2r9, providing insights into the dynamic interplay of signals that drive cellular responses and behaviors.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Non-specific inhibitor of phosphodiesterases, increases cAMP levels, potentially disrupting Vmn2r9-mediated signaling. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
SERCA inhibitor, raises intracellular Ca2+ levels, could affect calcium signaling related to Vmn2r9. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor, could interfere with MAPK/ERK pathways indirectly related to Vmn2r9 signaling. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
Calcium chelator, could disrupt intracellular calcium signaling pathways involving Vmn2r9. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
PKC inhibitor, could alter signaling pathways that intersect with Vmn2r9's function. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
Inhibits CaMKII, affecting calcium-dependent signaling pathways relevant to Vmn2r9. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor, could modulate AKT signaling pathways affecting Vmn2r9 function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor, might modulate stress response pathways related to Vmn2r9. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor, could influence apoptosis pathways potentially linked to Vmn2r9 signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor, further reinforcing the blockade of pathways potentially affecting Vmn2r9. | ||||||